MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic DiseasesGlobeNewsWire • Monday
MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing ConferenceGlobeNewsWire • 09/05/24
MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 GuidanceGlobeNewsWire • 08/06/24
MaxCyte (MXCT) is on the Move, Here's Why the Trend Could be SustainableZacks Investment Research • 07/17/24
Does MaxCyte (MXCT) Have the Potential to Rally 85% as Wall Street Analysts Expect?Zacks Investment Research • 06/13/24
MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and DevelopmentGlobeNewsWire • 05/22/24
MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 GuidanceGlobeNewsWire • 05/07/24
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)GlobeNewsWire • 04/02/24
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 GuidanceGlobeNewsWire • 03/12/24
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary ResultsGlobeNewsWire • 03/04/24
MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor ConferencesGlobeNewsWire • 02/09/24
MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen's Investigational Allogeneic, Off-the-Shelf Cell Therapies for CancersGlobeNewsWire • 01/30/24
MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy ProgramsGlobeNewsWire • 01/23/24
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewsWire • 01/08/24
MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell PipelineGlobeNewsWire • 01/03/24
MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and DirectorGlobeNewsWire • 01/02/24